Iterum Therapeutics plc

ITRM42

Penny Stock

$1.05arrow_drop_down3.66%-$0.04

Penny Stock

ITRM42

$1.05

arrow_drop_down3.66%-$0.04

Penny Stock

Performance History

Key Stats
Open	$1.10
Prev. Close	$1.09
EPS	-1.83
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$24.74M
PE Ratio	-

	LOW	HIGH
Day Range	0.99	1.10
52 Week Range	0.62	2.50

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-1.83

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Iterum Therapeutics plc (ITRM)

Iterum Therapeutics plc (ITRM) is a pharmaceutical company focused on the development of innovative anti-infectives for diseases caused by multi-drug resistant pathogens. The company's mission is to provide safe and effective treatment options for patients with serious infections that have limited or no alternative therapies available. With a strong pipeline of potential drug candidates, Iterum is well-positioned to address the growing threat of antibiotic resistance and make a significant impact on public health.

One of Iterum's most promising drug candidates is sulopenem, a novel oral and intravenous antibiotic being developed for the treatment of uncomplicated urinary tract infections (uUTIs). Sulopenem has shown excellent efficacy and safety in clinical trials, and the company is currently seeking approval from the U.S. Food and Drug Administration. If approved, sulopenem could become a valuable treatment option for patients with uUTIs, a common and often recurrent condition that affects millions of people worldwide.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Corey N. Fishman
Headquarters: Dublin
Employees: 14
Exchange: NASDAQ

add Iterum Therapeutics plc to watchlist

Keep an eye on Iterum Therapeutics plc

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Iterum Therapeutics plc's (ITRM) price per share?

The current price per share for Iterum Therapeutics plc (ITRM) is $1.06. The stock has seen a price change of -$0.04 recently, indicating a -3.67% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Iterum Therapeutics plc (ITRM)?

For Iterum Therapeutics plc (ITRM), the 52-week high is $2.5, which is 138.1% from the current price. The 52-week low is $0.62, the current price is 68.81% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Iterum Therapeutics plc (ITRM) a growth stock?

Iterum Therapeutics plc (ITRM) has shown an average price growth of 0.41% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Iterum Therapeutics plc as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Iterum Therapeutics plc (ITRM) stock price performance year to date (YTD)?

As of the latest data, Iterum Therapeutics plc (ITRM) has a year-to-date price change of -46.84%. Over the past month, the stock has experienced a price change of -21.64%. Over the last three months, the change has been -8.7%. Over the past six months, the figure is -36.36%. Looking at a longer horizon, the five-year price change stands at -98.89%.

help

Is Iterum Therapeutics plc (ITRM) a profitable company?

Iterum Therapeutics plc (ITRM) has a net income of -$38.37M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$47.47M. Furthermore, the EBITDA is -$37.36M.

help

What is the market capitalization of Iterum Therapeutics plc (ITRM)?

Iterum Therapeutics plc (ITRM) has a market capitalization of $24.75M. The average daily trading volume is 337.68K, indicating the stock's liquidity and investor engagement.

News

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections

HEALTH

6/21/2024

Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections